From 8 to 10 December 2017, ALS/MND researchers, advocates and people living with ALS/MND from across the world, flew into Boston, USA to learn about and discuss the most recent developments in ALS/MND research at the 28th International Symposium on ALS/MND. You can watch the recap
An Australian trial of the drug Tecfidera for MND was reported in 'The Age' newspaper on 21 December. The Australian TEALS (Tecfidera in amyotrophic lateral sclerosis) study is a multi-centre Phase 2 clinical trial to investigate the safety, tolerability and effectiveness of a drug called Tecfidera in people with MND. Tecfidera is currently used to treat relapsing multiple sclerosis (MS) in Australia by slowing down the progression of physical disability of MS.
Thank you to Nick Moretti from the Newcastle Italian Film Festival for your continued support and donation of $15,000. This is the fourth year that MND NSW has been supported by the festival. Pictured is Nick Moretti (left) and Graham Opie, CEO MND NSW.
Advance is the newsletter of the MND Research Institute of Australia - the research arm of MND Australia.
This is the third year that staff from the Department of the Environment and Energy in Canberra have supported our association with an Ice Bucket Challenge. The event, now known as The Scott Lisle Memorial Ice Bucket Challenge, is held in memory of a former colleague. We would like to thank Tara McGowan and Phil Bates who coordinate the event, and everyone who generously donated. A fantastic $7,000 was raised. Thank you for the continued support!
